There are 2789 resources available
1201P - Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK+ advanced NSCLC with or without baseline CNS metastases (mets)
Presenter: Matthew Krebs
Session: ePoster Display
1242P - Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
Presenter: Yajun Ji
Session: ePoster Display
1243P - Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status
Presenter: Evan Strom
Session: ePoster Display
1244P - Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)
Presenter: Mircea Dediu
Session: ePoster Display
1245P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
Presenter: Ruifen Tian
Session: ePoster Display
1246P - A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
Presenter: Toyoaki Hida
Session: ePoster Display
1247P - Management of infusion-related reactions (IRRs) in patients receiving amivantamab
Presenter: Keunchil Park
Session: ePoster Display
1248P - Osimertinib and crizotinib cardiotoxicity: Are real-world studies the way forward?
Presenter: Hasan Kobat
Session: ePoster Display
1249P - Pharmacokinetic and dose finding study of osimertinib in patients with impaired renal function and low body weight
Presenter: Tetsunari Hase
Session: ePoster Display